# A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

> **NCT03532880** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Small-cell Lung Cancer
- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Olaparib Pill 50 mg
- **DRUG:** Olaparib Pill 100 mg
- **DRUG:** Olaparib Pill 150 mg
- **DRUG:** Olaparib Pill 200 mg
- **DRUG:** Olaparib Pill 250 mg
- **DRUG:** Olaparib Pill 300 mg
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT03532880
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-12
- **Primary completion:** 2025-02-04
- **Final completion:** 2025-02-04
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03532880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03532880, "A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03532880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*